Company News: Bristol-Myers Squibb, Pfizer, Xanodyne Pharmaceuticals and Human Genome Sciences
Bristol Myers-Squibb and Pfizer ended a Phase III clinical trial of anticoagulant apixaban in patients with acute coronary syndrome.
Your Email Address: *
Recipient(s) Email Address: *
(Separate multiple e-mail addresses with commas. Limited to 20 addresses.)
The e-mail address(es) that you supply to use this service will only be used to send the requested article.